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Coronary artery disease in uremia: Etiology, diagnosis, and ther- leagues for support, advice and expertise. However, there
apy. Cardiovascular disease is a major challenge to nephrolo- are important differences in pathophysiology, pharma-
gists, whether we deal with patients with pre–end-stage renal cology, and prognosis between “renal patients” and non-failure, on dialysis or after successful renal transplantation. It is
renal subjects. It is the purpose of this review first tothe most common cause for death in patients with a functional
identify facets of renal diseases and their treatments thatallograft, and prevents many dialysis patients from being en-
grafted. Coronary artery disease is a diagnostic and therapeutic mandate a different approach to cardiological problems
challenge, as it differs in some respects from that seen in non- in renal patients, and second to assess in detail the evi-
uremic cohorts, and lacks much of the evidence-base on which
dence that is available to support therapeutic decision-therapeutic intervention rests. This review examines the experi-
making in a body of patients in which typically there ismental and clinical literature on cardiovascular disease in ure-
mia, focusing on coronary artery disease. We focus on the a complex interplay between both renal and non-renal
incidence, presenting syndromes, screening tools, and interven- co-morbidities.
tions in the context of acute and chronic coronary syndromes.
Recent evidence comparing coronary angioplasty, coronary
artery stenting, and bypass surgery in subjects with renal failure ATHEROGENESIS IN PATIENTS WITH
is also reviewed. Coronary artery disease is more prevalent in RENAL DISEASEuremia, more difficult to diagnose and less rewarding to treat
compared to non-uremic subjects. Many more randomized tri- The first reports of “accelerated atherosclerosis” (see
als are needed. In the absence of information from such trials, later) in patients on dialysis were in the 1970s, though
we advocate aggressive control of conventional and novel car- reading these articles it is clear that the process con-diovascular risk factors, and early intervention for symptomatic
cerned was as much arteriosclerosis as atherosclerosiscoronary disease.
[6]. The prevalence of surrogate (carotid intima-media
thickness using B-mode Doppler ultrasound), sub-clini-
cal (carotid plaques, coronary lesions), or clinically overtThe morbidity and mortality from cardiovascular dis-
atheromatous disease is greatly increased in renal failureease (CVD) is greatly increased in patients with renal
compared to control subjects [7].impairment, on dialysis and after renal transplantation
Atherogenic factors include the widespread, if not(Fig. 1) [1–3]. This increased CVD risk is only partly
ubiquitous (for nutritional reasons) dyslipidemia of renalaccounted for by “traditional” CVD risk factors and is
disease, tending to hypertriglyceridemia in 50 to 75%especially marked in patients with severe renal impair-
of chronic renal failure and dialysis patients often withment and in those on dialysis [4, 5]. Cardiac mortality
normal low-density lipoprotein (LDL)-cholesterol levels.can arise from arrhythmia, cardiomyopathy, and from
In the nephrotic syndrome and after renal transplanta-coronary artery disease. This review focuses on clinical
aspects of the last of these causes. tion hypercholesterolemia is the main abnormality [8].
As many of the long-term problems that afflict patients The genesis of these lipid problems is multifactorial and
with renal disease are cardiovascular, nephrologists al- poorly understood. Important mechanistically is the loss
ways will rely very heavily on their cardiological col- or dysfunction of key lipid metabolic enzymes (lipopro-
tein lipase, hepatic lipoprotein lipase, lecithin cholesterol
acetyltransferase and cholesterol ester transfer protein)Key words: low-density lipoprotein, angiotensin-converting enzyme,
electrocardiography, computed tomography, heparin, asprin. leading to dysmetabolism of triglycerides and defective
reverse cholesterol transport. This then leads to enrich-Received for publication October 24, 2000
ment of very low-density lipoprotein (VLDL) with bothand in revised form April 17, 2001
Accepted for publication July 11, 2001 triglyceride and cholesterol moieties (and enrichment of
LDL with cholesterol moieties), and also to the accumu- 2001 by the International Society of Nephrology
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Fig. 1. Mortality rates for dialysis and transplant patients in the United
States compared with age- and gender-matched normal subjects. Data
are from 1998 USRDS data. (Publication of this figure in color was made
possible by a grant from the Genzyme–Geltex Corporation, Cowley, Fig. 4. Reversible perfusion defects on myocardial nuclear scintigra-
England, United Kingdom.) phy. In both panels (A and B), the images appear as pairs (upper image
“stress” and lower image “rest”). Panel A is a dobutamine stress study
and shows reversible perfusion defects indicative of ischemia. Panel B
is an adenosine-myoview scan and shows a fixed perfusion defect and
a dilated left ventricle. (Publication of this figure in color was made
possible by a grant from the Genzyme–Geltex Corporation, Cowley,
England, United Kingdom.)
seen in uremia, and malnutrition and accelerated athero-
sclerosis [15]. Close interdependent links between chronic
low-grade inflammation on the one hand, and malnutri-
tion and atherosclerosis on the other, seem entirely con-
sistent with the epidemiology of these parameters in
uremic patients. Finding ways to “quench” the microin-
flammatory state may then permit improvements in nu-
Fig. 5. An example of an electron beam (ultrafast) computed tomogra- trition and vascular disease. Thus far, lipid-lowering ther-
phy (EBCT) scan showing significant coronary artery calcification in a
apy and angiotensin-converting enzyme (ACE) inhib-dialysis patient. Calcium shown as blue in the left panel. (Photo courtesy
of Paulo Raggi, M.D., Tulane University, New Orleans, LA, USA. Pub- ition have been shown to reduce C-reactive protein
lication of this figure in color was made possible by a grant from the (CRP) values as well as blood pressure (BP) and choles-
Genzyme–Geltex Corporation, Cowley, England, United Kingdom.)
terol [16, 17], but not in uremic populations.
The prevailing metabolic milieu in moderate-to-severe
chronic renal failure and on dialysis strongly seems to fa-
vor an increased rate of atherosclerosis, and atheroscle-lation of lipoprotein(a) [9] and intermediate-density li-
rotic/thrombotic events, in these patients. It is often statedpoproteins [10].
that atherosclerosis is “accelerated” in uremia; however,The elevation of fibrinogen, lipoprotein(a) and homo-
this term is ambiguous and used imprecisely to cover in-cysteine, typically seen in renal failure patients [11], is
creased prevalence, or an increased number of athero-thought to be highly pro-“thrombotic” [12]. An increased
sclerotic lesions in individual patients. Formal proof ofincidence of vascular access occlusive events in relation
the “acceleration” of atherosclerosis (that is, increasedto elevation of homocysteine has been reported in some
rate of atherosclerosis progression using serial measure-[13] but not other [14] dialysis patients.
ments in a cohort of patients, with diabetic, or hyperten-A recent area of intense interest to nephrologists is
the relationship between the “micro-inflammatory” state sive cohorts as controls) is lacking. Indeed, its very exis-
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tence in uremia has been called into question, once the lar infiltrate in coronary arteries showed no major differ-
ences in these advanced plaques of uremic and non-uremicco-existence of hypertension, dyslipidemia and diabetes
are taken into account [18]. These three predispositions subjects. Coronary plaques in patients with end-stage
renal failure were characterized by increased media thick-are likely to explain much of the raised prevalence of
atherosclerosis in uremic populations. There is an over- ness and marked calcification. Thus, the most marked
difference compared to non-uremic controls concernswhelming lack of prospective trial-based evidence to
guide practice, which therefore has been forced to rely not the size, but the composition of the plaque. Raised
plasma phosphate is associated with increased ectopic(too heavily) on extrapolation from other patient groups
such as aged, diabetic, hypertensive and hyperlipidemic vascular [23] and cardiac [24] calcification, and is linked
to increased time [25] and mortality on dialysis [26]. Itsubjects.
may be that deposition of calcium within the plaques
contributes to the high complication rate in uremic pa-
CORONARY ARTERY DISEASE
tients; however, some recent ex vivo human coronary
This section considers in sequence the prevalence and artery studies suggest that calcified plaque is in fact stable
associations of coronary-angiographically documented [27]. A typical angiogram (from a patient dialyzed for 23
epicardial coronary artery disease (CAD); small vessel years then successfully transplanted, but then developing
coronary disease; CAD symptomatology; CAD screen- crescendo angina requiring triple CABG) is shown as
ing techniques; medical treatment of acute and chronic Figure 2.
coronary syndromes; and finally the evidence for and Cross-sectional studies examining the relationship of
against intervention with coronary angioplasty, coronary conventional and novel cardiovascular risk factors, and
stenting and coronary artery bypass grafting (CABG). the prevalence and severity of clinical/angiographic CAD
have shown that lipid concentrations, lipoprotein(a)
Prevalence
[Lp(a)] levels, apolipoprotein levels, and fibrinogen ten-
Angiographically confirmed prevalence of significant ded to be higher in hemodialysis patients with CAD as
(50%) stenoses in the epicardial coronary arteries of opposed to those without it. However, these parameters
course will vary depending on the index population re- had a very poor predictive value for CAD [28]. The
ported. Reports vary from 24% prevalence in a young, frequency of low molecular weight isoforms of Lp(a)
non-diabetic hemodialysis population undergoing evalu- (atherogenic) was significantly greater in CAD patients,
ation for renal transplantation [19] to 85% in long-stand- and this point was confirmed in another follow-up ad-
ing diabetic dialysis patients over 45 years old [20]. Given verse events study in hemodialysis patients [29].
that the median age of patients currently accepted for There are very few reports of the factors that influence
dialysis in the United Kingdom (and North America) is progression of established CAD in uremic patients. In
around 60 years old, with one-third of the patients having a recent report 26 patients were assessed by coronary
diabetes, it is likely that about half of these patients have angiography at a mean interval of 30  15 months [30].
significant coronary lesions. Baseline angiography revealed CAD (stenosis 50%)
The nature and distribution of coronary atheroscle- in 59% of patients, and using quantitative angiographic
rotic lesions have not been intensively studied. However, techniques identifying 45 coronary segments, progres-
there is a much greater frequency of complex-calcified sion (15% luminal reduction) was shown in 17 of 45
atheroma in uremic patients’ coronary arteries. In this segments, de novo CAD in nine segments resulting in
respect the disease in uremics resembles the coronary progression or new lesion in 62% of patients. However,
disease seen in diabetic patients [21]. A recent important there was no measurable difference between the progres-
study by Ritz’s group in Heidelberg has examined post- sion/de novo group and the stable group with respect
mortem coronary disease in dialysis and control patients to gender, age, duration of dialysis, cardiovascular risk
[22]. Qualitative analysis of the coronary arteries showed factors, lipid fractions or fibrinogen levels.
significantly more calcified plaques of coronary arteries
Implications of the presence of CADin patients with end-stage renal failure. Plaques of non-
uremic patients were mostly fibroatheromatous. Media The significance of ischemic heart disease symptoms
thickness of coronary arteries was significantly higher in for dialysis patients is great. In Parfrey et al’s study to de-
uremic patients (187  53 m vs. 135  29 m in con- termine the prognosis and risk factors for ischemic heart
trols) and intima thickness tended to be higher (158  disease in chronic uremia, a cohort of 432 dialysis pa-
38 m vs. 142  31 m), but this difference was not sta- tients was followed prospectively from the start of dialy-
tistically significant. Plaque area (4.09  1.50 mm2 vs. sis therapy until death or renal transplantation [31]. Base-
4.39 0.88 mm2) was comparable in both groups. Lumen line demographic, clinical and echocardiographic data
area, however, was significantly lower in the end-stage were obtained. After the initiation of dialysis laboratory
data were collected at monthly intervals, and clinical andrenal patients. Immunohistochemical analysis of the cellu-
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ease, not evident on starting dialysis therapy, occurred
in 41 (9%) patients. When compared to patients who
never developed ischemic disease (N  296; 69%), sig-
nificant and independent predictors of de novo disease
were older age (P  0.0007), diabetes mellitus (P 
0.0001), high blood pressure during follow-up on dialysis
(P  0.02) and hypoalbuminemia (P  0.03), whereas
anemia was not an independent predictor. Left ventricu-
lar (LV) mass index was 174  7 g/m2 in those who
developed de novo ischemic disease compared to 155 
3 g/m2 (P  0.001) in those who did not. Concentric LV
hypertrophy, LV dilation and systolic dysfunction were
independent risk factors for de novo ischemic heart dis-
ease. They concluded that ischemic heart disease oc-
curred frequently in dialysis patients, its adverse impact
was mediated through the development of heart failure,
and most importantly, its potentially reversible risk fac-
tors were hypertension, hypoalbuminemia, and underly-
ing cardiomyopathy.
Inflammatory and aneurysmal CAD
Brief mention should be made of non-atheromatous
causes of epicardial coronary artery disease. Coronary
vasculitis in Wegener’s granulomatosis [32], Churg-
Strauss syndrome [33], Henoch-Scho¨nlein purpura [34]
and systemic lupus erythematosus [35] are rare, but
known. Aneurysms of the coronary arteries have been
seen in classical polyarteritis nodosa [36], in Kawasaki
disease of children [37], Churg-Strauss syndrome [38],
fibromuscular dysplasia [39], and autosomal polycystic
kidney disease [40].
Coronary arteriolar pathology
The incidence and pathology of small vessel/myocar-
dial arteriolar disease in uremic patients is not known.
However, like diabetes, uremic arterial changes occur in
Fig. 2. A coronary angiogram from a patient dialyzed for 25 years who
both large and small vessels. Arteriolar and capillaryhad a renal transplant and developed angina pectoris. Severe diffuse
coronary disease is seen. growth dysregulation are described in an elegant review
by Ritz and Amann [41]. In hypertension, such small
vessel disease is recorded, and may play an important
role in impairment of cardiac vasodilator reserve [42].
echocardiographic data at yearly intervals. Twenty-two Cardiac and renal amyloid can often co-exist, and arteri-
percent of patients (N  95) either had a history of olar involvement by amyloidosis is a cause of “ischemic”
angina pectoris or myocardial infarction on starting dial- chest pain [43]. Myocardial involvement in the rare and
ysis therapy. Median time to onset of heart failure was mysterious condition of calciphylaxis (uremic calcific
24 months in those with ischemic heart disease on initia- obliterative arteriolopathy with tissue necrosis [44]) has
tion of dialysis, compared to 55 months in those without been reported rarely [45]. Figure 3 shows micro-vascular
(P  0.0001). This effect was independent of age, diabe- occlusive coronary artery disease (CAD) with patent
tes and underlying cardiomyopathy. Median survival was epicardial coronary arteries.
44 months in those with ischemic disease compared to
Symptomatology56 months in those without (P  0.0001). While this
adverse impact was independent of age and diabetes Angina pectoris is a very frequent symptom in dialysis
mellitus, when cardiac failure was added to the Cox’s patients. Indeed, the prevalence of angina significantly
model, ischemic heart disease was no longer an indepen- exceeds the prevalence of CAD. Even in a young group
of dialysis patients with little co-morbidity, 26% of 382dent predictor of survival. De novo ischemic heart dis-
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Fig. 3. Normal epicardial arteries with severe
intra-myocardial arteriolar disease (A) and in-
timal and medial hyperplasia with luminal
obliteration by in situ thrombosis (B).
patients experienced classical angina in Rostand et al’s ity that is often seen in dialysis patients adversely affects
aortic blood flow [53] and subendocardial perfusion [54]report [46]. The apparent paradox of angina with open
coronary arteries has been widely confirmed [47]. in diastole.
The converse situation, namely severe CAD with noReasons for this include severe anemia (rare in the
modern age with erythropoietin), intra-myocardial CAD symptoms, is even more common. The authors have seen
totally asymptomatic, fully ambulatory patients with crit-and reduced vasodilator reserve [48], abnormal endothe-
lial vasomotor function [49], cardiac dysautonomia [50], ical lesions of the left mainstem coronary artery. Braun,
Phillips and Vidt reported that 75% of their (diabetic)imbalance between oxygen supply to, and demand from,
the myocardium, which is a consequence of all left ven- patients with angiographically significant CAD had no
symptoms [55]. In Koch et al’s study of 105 consecutivetricular hypertrophy, intense inter-cardiomyocyte fibro-
sis [51], and also impaired cellular energy utilization [52]. diabetic patients embarking upon dialysis therapy, only
9 out of 38 patients with CAD (stenoses 50%) hadIt is likely that the marked reduction in aortic distensibil-
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symptoms [28]; a similar study in a mixed diabetic/non- Assay-related problems, especially for troponin I [69],
and the detection of myocardial troponin isoforms fromdiabetic group of dialysis patients found that only 43%
had symptoms [56]. The reasons for this include uremic skeletal muscle in uremic patients [70] have led to the
reporting of reduced sensitivity of these markers in ure-autonomic neuropathy [57] (akin to diabetes), and also
in some patients a sedentary lifestyle. mia [71].
Other symptoms can certainly herald CAD. Exer-
Nuclear scintigraphic screeningtional breathlessness can be helpful, but here, anemia,
LV systolic and diastolic dysfunction, fluid overload, and This technology has been used most extensively in the
evaluation of patients near or at end-stage renal failuresystemic acidosis vastly reduce the specificity of this
symptom. Arrhythmias, especially during hypotensive- who are on dialysis for potential renal transplantation.
Transplantation is the only definitive therapy for uremia,episodes as often occur during hemodialysis sessions,
also can be due to myocardial ischemia [58]. and survival well beyond that expected on dialysis is the
goal [72].
Electrocardiography The cardiovascular risk from renal transplantation is
a composite of the anesthesia, ischemic burden, and leftResting electrocardiograms (ECGs) are often abnor-
mal in dialysis patients, with minor incremental changes ventricular performance. Asymptomatic individuals can
be screened for ischemic burden by exercise and pharma-in the PR and QRS intervals, and non-specific changes
in ST-T waves (marked alterations in plasma potassium, cological stress testing. There are conflicting accounts in
the literature of the usefulness of nuclear medicine incalcium and magnesium occur across dialysis sessions).
Dialysis per se changes the amplitude of the QRS com- the evaluation of the ischemic burden in this context,
and this has been reviewed recently [73].plex due to reduction in extracellular water [59]. The
high prevalence of left ventricular hypertrophy also im- In one study of 45 patients, five out of the six who
died of cardiac causes in the ensuing 25 months hadpacts on the resting (and exercise) ECG. In acute coro-
nary syndromes (unstable angina and myocardial in- normal dipyridamole-thallium scans [74]. In another
study of 80 patients, 36 had normal thallium imagingfarction), the classical ECG changes seem to occur
normally. studies, but six of these had significant CAD by angiogra-
phy [75]. However, Le et al found that patients withAmbulatory ECG recordings have not been inten-
sively studied in dialysis patients. Two reports provide reversible thallium defects had a significantly higher
mortality rate than those without (23% vs. 5%, P evidence of a large cohort of patients with asymptomatic
ST-T segment changes, especially during and after dial- 0.001), and interestingly that fixed as opposed to revers-
ible defects also were predictive of future cardiovascularysis [60, 61]. Whether this reflects occult coronary dis-
ease, or electrocardiographic responses to major trans- death, but at a later period [76]. A reversible defect on
myocardial nuclear scintigraphic scanning is shown ascellular shifts in potassium, calcium and magnesium, has
not been determined. Figure 4.
Dahan’s study tested the diagnostic and prognosticExercise-electrocardiography is limited by abnormal
resting ECG and by the markedly reduced exercise ca- accuracy of a combined dipyridamole-exercise thallium
imaging in dialysis patients. Dipyridamole-exercise thal-pacity of most dialysis patients (muscle fatigue, joint prob-
lems, anemia) and by a blunted or absent tachycardia lium imaging and coronary angiography were both per-
formed prospectively in 60 asymptomatic hemodialysis(autonomic neuropathy). For whatever reason, 80% of
patients will not achieve a rise in heart rate that exceeds patients who were followed up long-term by recording
any major coronary event. Coronary angiography was85% of maximal predicted [62]. In Koch’s study ST-
segmental depression had a sensitivity of 52% for CAD. abnormal in 13 patients (21%), and there was abnormal
thallium uptake in 17 patients. Sensitivity, specificity,
Biochemical markers of left ventricular positive and negative predictive values, and overall accu-
function and ischemia racy of thallium to detect a coronary artery disease were
92, 89, 71, 98 and 90%, respectively. After a medianSerial measures of creatine phosphokinase (muscle-
brain isoform), CK-MB and lactate dehydrogenase (LDH) follow-up of 2.8 years, 12 patients experienced at least
one major coronary event (4 cardiac deaths, 5 myocardialenzymes are reliable in diagnosing acute myocardial in-
farction, but one-off values have poor specificity [63]. infarctions and 3 revascularizations). Eight of the 17
patients with abnormal thallium uptake (47%) sufferedRecently, much interest has been aroused in both tropo-
nin T [64] and troponin I [65] as putative markers of a coronary event, compared to only 4 of the 43 patients
(9%) with a normal thallium uptake (P  0.001). Theongoing ischemic damage in dialysis patients [63, 66].
Two recent large prospective trials suggest that troponin positive prognostic predictive value of thallium imaging
was 47% and its negative predictive value was 91%.T levels were useful independent predictive markers of
cardiovascular mortality in dialysis patients [67, 68]. The probability of survival free of coronary events was
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significantly higher in patients with normal thallium up- Electron-beam ultrafast computed tomography
(EBCT)-derived coronary artery calcification (CAC)take than in those with abnormal thallium uptake (crude
risk ratio 7.6; P 0.001) even after adjustment for several This is another screening technique that has under-
risk factors for cardiovascular disease (adjusted risk ratio gone an explosion of interest in the last decade [81].
9.2; P  0.005). The authors concluded that in dialysis While doubts remain about the specificity of coronary
patients, combined dipyridamole-exercise thallium im- calcium for advanced atheroma, it has been possible to
aging was an accurate method for detecting coronary track coronary artery changes with treatment using this
stenosis and for predicting future coronary events. technique [82].
A recent study examined the relationship between cor- In renal patients however, both abluminal complex
onary disease, myocardial ischemia detected by exercise- atheromatous plaque calcification, and calcification in
the media of the vessel wall, are common in the aortastress myocardial perfusion imaging with 99mTc-MIBI
and great vessels, related to hypertension, duration of(methoxyisobutylisonitrite) and also myocardial sympa-
dialysis, and deranged calcium-phosphate balance [23].thetic activity using I123-MIBG (metaiodobenzylguanid-
Cardiac calcification also is common and significantlyine) corrected for perfusion (Tl201). Exercise-induced
greater than that seen in non-uremic subjects [24, 83, 84]perfusion abnormality was seen in 25 of 36 patients.
whether in valves, arteries, myocardium or pericardium.However, there were several patients where clear-cut ex-
Where these CT techniques have been used in parallelercise perfusion abnormalities occurred in myocardium
to coronary angiography in dialysis patients, the resultssupplied by normal epicardial coronary arteries but with
seriously question the article of faith on which thisabnormal sympathetic nervous system activity [50].
screening tool rests, namely that the presence of calciumAmong the problems encountered with these noninva-
in a coronary artery is a reliable surrogate for the pres-sive nuclear techniques include patients with blood pres-
ence of significant coronary artery atherosclerosis [85].sure levels either too high or too low safely to be adminis-
However, there is increasing evidence that increased car-tered a vasodilator agent, a high endogenous level of
diac calcium content is a poor prognostic sign in uremicadenosine, blunting the efficacy of dipyridamole [76],
subjects; progressive valve calcification [86] and dys-LVH and small coronary artery disease affecting coro-
rhythmias are rare but important adverse outcomes. Anary flow reserve [73], balanced or symmetrical large
study on dialysis patients using intracoronary ultrasoundcoronary disease, and dysautonomia blunting pharmaco-
to delineate coronary calcium deposition, coronary ath-logically-induced tachycardia. These practical problems
erosclerosis, and comparing these findings with EBCT-are relevant to the vexed issue of repeating non-invasive
screening, would be especially helpful [87].screening tests for patients still waiting on the transplant
It is clear though that cardiac (mainly coronary) calci-list (average wait is about 3 years in the UK). Over the
fication increases with both age and survival on dialysisage of 60 we advocate repeating these screening tests
[25, 84, 88]. Indeed the CAC scores from dialysis patientsevery 12 to 24 months (depending on the number of
are very significantly higher than those from non-uremic
known CAD risk factors present).
subjects with severe triple vessel CAD. Patients under the
age of 20, even if on dialysis for years, seem to be immuneStress-echocardiography
from CAC, probably because of relatively lower BP and
Left ventricular hypertrophy is very prevalent in ure- also an “open” skeleton (that is, continuing bone growth,
mia, especially in long-term dialysis patients [77]. The ex- with capacity to buffer excess calcium and phosphate).
tent of reversal of LVH after successful renal transplanta- Evidence to incriminate chronic elevation in calcium-
tion and those factors that facilitate this desirable outcome phosphate product, and both high- and especially low-
remain both undecided and controversial, though most turnover bone lesions, in the genesis of ectopic or vascu-
studies report substantial LV regression post-transplanta- lar calcifications is accumulating [89]. The widespread
tion [78]. However, LV function or size at renal trans- (over) use of vitamin D compounds (invariably raising
plantation is predictively important for survival [79]. plasma calcium), the inaccuracy of typical “intact” para-
Dobutamine-stress echocardiography is rapidly estab- thyroid hormone (PTH) assays by which their use is
lishing itself as an important screening tool. In the right calibrated [“intact” PTH is actually a composite of ade-
hands it is both safe and highly effective [73]. In the nylate cyclase-activating (1-84 PTH), and -inactivating
dialysis population, negative predictive values in excess PTH (7-84 PTH)], and the use of large doses of calcium-
of 95% have been reported in two studies with reason- containing oral phosphate-binders (as a result of fears
able subject numbers and follow-up periods [73, 80]. Any of long-term aluminium exposure) all conspire to induce
influence that the timing of the investigation might have a strongly-positive calcium balance. As phosphate bal-
in respect of the hemodialysis sessions (and fluid status) ance despite phosphate-binders is often positive in dial-
ysis patients, the combination of excess calcium andhas not been commented on.
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phosphate intake with reduced skeletal buffering capac- Screening strategies
ity may unwittingly be accelerating this phenomenon In the early days of renal transplantation, acute coro-
[90]. Trials using the novel non–calcium-containing com- nary syndromes in the early post-operative period were
pound Sevelemer (Renagel) to assess the rate of progres- commonplace and patient death rates high due to cardio-
sion of CAC in dialysis patients have recently shown vascular disease and from overwhelming infection. In
stabilization of CAC compared to steady progression in the modern age, the careful cardiovascular evaluation
a similar cohort given calcium acetate. An outcome study of prospective recipients to select those who may benefit
relating CAC to survival is now awaited with special most (by longevity) from this very scarce resource seems
interest. The effect of renal transplantation on CAC is both logical and desirable.
also unknown. The American Society of Transplant Physicians rec-
An example of an EBCT scan showing CAC is in ommends screening all potential transplantation patients
Figure 5. except those at the very lowest risk [95]. Despite less
than ideal sensitivity and specificity, almost every renalCoronary angiography
transplantation unit will make some use of pharmacolog-
Given the many limitations of all of the noninvasive ical nuclear scintigraphy tests. It is likely that in these
screening tools mentioned, it is clear that only coronary higher-risk uremic patients, several (rather than relying
angiography can truly estimate the presence and severity on one) screening tools will be needed to complete the
of coronary artery disease. For the general population assessment. Most transplantation centers operate a cas-
it is the definitive investigation to provide information cade algorithm to select “at risk” patients for more inten-
to guide critical decision-making about the choice of sive cardiac investigations, culminating in angiography.
therapy; patient survival can be directly related to the A number of these have been elaborated for diabetic
ischemic burden [91]. In contrast, we know relatively [20, 28] and non-diabetic patients [96, 97].
little about the prognosis of CAD lesions in uremic pa- A few caveats should be considered in the use of indi-
tients, so there is a much smaller evidence-base from rect screening. First, one must not fail to remember that
which to formulate therapeutic decisions. the risks and benefits of screening for CAD in this patient
For reasons of demand pressures, costs, increased
population have not been studied nearly as exhaustively
morbidity and genuine uncertainty about how to manage
as they have in the general as well as other high-risk
asymptomatic patients, it is very unusual to find trans-
populations. Second, what has not been successfully eval-plant units able to achieve 100% cardiac catheterization
uated is the repeated use of these indirect non-invasiverates in putative transplantation candidates. Formal
tests in the same patient as he/she waits for renal trans-comparisons of the complication rates from coronary
plantation.angiography for dialysis patients are not available. In
Cardiac catheterization remains a crucial tool bothpatients with residual renal function there is concern
to select for transplantation patients with anatomicallyabout contrast nephropathy, though this risk can be re-
unimportant coronary lesions (in whom noninvasive test-duced by careful patient selection and avoidance of dehy-
ing may have given equivocal or misleading informa-dration. Even with more prolonged procedures such as
tion), and also to screen out patients with “high-risk”angioplasty, there is a very low incidence of clinically
coronary anatomy for revascularization or for permanentsignificant deterioration of renal function [92]. Adequate
exclusion from transplantation.hydration of such patients is paramount; furosemide may
well be detrimental in renoprotection [93]. A recent re-
port of the use of oral N-acetyl cysteine as a renoprotec- MANAGEMENT OF CORONARY
tive maneuver against contrast nephropathy is very inter- ARTERY DISEASE
esting [94].
Acute coronary syndromesIn Pidgeon et al’s study of 89 patients subjected to
Controlled long-term studies in uremic patients arecoronary angiography for transplantation evaluation, to-
missing. However, American data strongly suggest thattal mortality for those patients with three and four vessel
for undetermined reasons, dialysis patients to not receivedisease was significantly greater than that for patients
therapies that are routine in non-uremic patients. Herzogwith no, one and two vessel disease (which groupings
showed that few dialysis patients with acute myocardialdid not differ one from another) [56]. Thirteen patients
infarction in America receive thrombolytic therapy,were debarred from renal transplantation on account of
which may explain their poor short- and long-term sur-severe coronary disease. In this analysis, restriction of
vival [98, 99]. Chertow et al’s recent report derived fromcoronary angiography to all diabetics, and those with
640 ESRD patients with a myocardial infarction (MI)cardiac symptoms and/or history would have resulted in
between 1994 and 1995 revealed a 53% one-year sur-63% fewer angiograms with the same implication for the
renal transplantation waiting list. vival. Advanced age, low or high body mass index, his-
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tory of peripheral vascular disease or stroke, and cardiac hypertension). Dialysis also should be used to control
extracellular fluid volume carefully. Avoiding low/nor-dysfunction all were associated with an increased rela-
tive-risk of death [100]. Hase et al’s study of 70 consecu- mal potassium and magnesium, most likely to occur im-
mediately after a hemodialysis session (and preventabletive HD patients suffering an acute coronary event
showed that coronary events were most frequent in the by altering the composition of the dialysis bath), or in
the recovery phase of renal function seen after acutefirst year of hemodialysis, and that long-term survival
was especially poor in the 65-year-old cohort [101]. renal failure or successful renal transplantation, are sen-
sible precautions to take in the context of acute myocar-Revascularization did not seem to influence the eventual
cause of patient death. dial infarction with the greatly increased risk of malig-
nant arrhythmias.Renal transplantation patients seem to fare rather bet-
ter, which in part must reflect their careful selection Lipid-lowering therapy. Later secondary prevention
measures should include lipid-lowering therapy with athereby avoiding overwhelming cardiovascular disease
burden [102]. Using the massive resources of the USRDS target cholesterol of 5 mmol/L, most safely achieved
with 3-hydroxy-3-methylglutaryl coenzyme A (HMGdatabase 783,171 patients were used retrospectively to
examine outcomes of renal transplant recipients hospi- CoA) reductase (statin) drugs. The incidence of rhabdo-
myolysis is no higher in dialysis patients on low-mediumtalized during 1977 to 1996 for a first (AMI) after initia-
tion of renal replacement therapy, long-term survival dose statins than it is in non-renal patients [108]. Care
should be exercised with statins and calcineurin-inhibi-was estimated by life-table method, and independent
predictors of survival were examined in a comorbidity- tors used as immunosuppression after renal transplanta-
tion because of cytochrome P450 systems interactions, andadjusted Cox model. There were 4250 renal transplant
recipients with AMI. The in-hospital death rate was in this regard pravastatin has fewer known drug interac-
tions than other statins [108, 109].12.8%. Overall 2-year cardiac and all-cause mortality
rates were 11.8  0.6% (SE) and 33.6  0.8%, respec- Angiotensin-converting enzyme inhibitors. In the light
of the HOPE trial, angiotensin converting enzyme inhibi-tively. The poorest survival after AMI occurred in pa-
tients with diabetic ESRD, with two-year cardiac and tors should be considered, though dialysis hypotension,
hyperkalemia, and renal transplant arterial stenosis mayall-cause mortality rates of 14.9 1.1% and 40.5 1.4%,
respectively. In the Cox model, the risks for cardiac and preclude their safe employment [110].
Hematocrit. The optimum (pre-hemodialysis) hema-all-cause death from AMI were 51% (P  0.0003) and
45% less (P  0.0001) in 1990 to 1996 compared with tocrit in both the acute and chronic setting remains to
be established, though it is likely to lie in the range of1977 to 1984, respectively. The long-term survival of
renal transplant recipients in the United States after 33 to 36% ([111]; discussion of the NKF-DOQI recom-
mendations in [95]). Avoidance of “reactive” polycythe-AMI has markedly improved in the modern treatment
era. Patients with diabetic ESRD experienced the worst mia (rarely seen after renal transplantation) also seems
prudent.outcome.
Many secondary preventive measures are clearly ben- Calcium-phosphate-PTH axis. Because of the highly
calcified nature of the coronary lesions, better controleficial in the non-renal patient acute myocardial in-
farction setting, and it seems reasonable to use these of calcium-phosphate product, hyperparathyroidism, and
scrupulous monitoring of vitamin D levels [112] alsoin renal patients. Acutely, thrombolysis, beta-blockade,
control of BP, optimization of hematocrit and some form should be medium-term goals.
Homocysteine. Raised homocysteine levels (10mol/of anti-platelet therapy are recommended. It should be
remembered that the dose of atenolol, but not labetolol L) should be treated with oral folate or B12 supplementa-
tion. Although there are no prospective studies of theor metoprolol, should be reduced in significant renal
failure [103]. Beta-blockers are especially helpful in dial- efficacy of long-term reductions in plasma homocysteine
in reducing future cardiovascular complications (that is,ysis patients, where the incidence of sudden death is
greatly increased [104], prolonged/regionalized electrical secondary prophylaxis), the therapy is harmless, cheap,
and useful hematologically. The evidence base is nodepolarization currents (late potentials on signal-aver-
aged ECG) [105] and repolarization abnormalities [106] weaker here than for many other areas.
Antiplatelet therapy and anticoagulation. Uremic pa-are common, and malignant ventricular arrhythmias are
more frequent [107]. The malign influence of cigarette tients already possess an acquired functional platelet de-
fect favoring hemorrhage [113] and an increased bleed-smoking on cardiovascular and general health is well-
known. All patients with any degree of renal impairment ing tendency is possible. However, increased platelet
adhesiveness in atherosclerotic uremic patients had beenshould very strongly be advised to desist.
Blood pressure, extracellular fluid volume and electro- reported [114, 115]. Thus, both thrombotic and bleeding
diatheses may be manifest.lytes. Special care must be taken to establish stable blood
pressure (avoiding hypotension, and tempering severe (a) Aspirin diminishes platelet aggregation. This effect
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may be exaggerated in uremic patients [116]. Theoretical ated impairment of diastolic function [77]; thus, coronary
perfusion improves by reducing the heart rate. Nicoran-worries about excessive anticoagulation include the si-
multaneous regular use of systemic heparinization for dil is well tolerated, though its intense vasodilatory action
may prove problematic immediately post-hemodialysishemodialysis, increased prevalence of poorly-controlled
BP, and in one recent trial, an increase in prosthetic if the patient is volume-depleted or hypotensive. Nitrates
are also well tolerated, and may improve coronary perfu-graft vascular access thrombosis in patients taking aspirin
[117]. However, another study of vascular graft uptake sion by partially correcting the marked abnormality in
pulse-wave energy characteristics (caused by increasedof radiolabeled platelets found that this was inhibited
efficiently by both aspirin and clopidrogel [118]. wave energy reflection at distal arterioles) that are seen
in many dialysis patients. Low-dose aspirin is also recom-Despite these concerns, the secondary preventive ef-
fect of aspirin in the general population is so significant mended.
To deny patients with renal disease and these coronary[119] that its use (at low dose) in this context seems
highly prudent. syndromes the above measures because of a lack of for-
mal evidence of benefit in this clinical setting is in our(b) Recently, fractionated (low-molecular-weight;
LMW) heparins have been used increasingly to achieve judgment counter-intuitive.
anticoagulation in unstable angina [120]. However, as
ELECTIVE CORONARYwith many small peptides, LMW heparins accumulate in
REVASCULARIZATIONchronic renal failure, and their action becomes less pre-
dictable, with potentially prolonged anticoagulant action It is particularly in this most important therapeutic
area that we find the evidential substrate so unsatisfac-if continued (and the reversal of fractionated heparin is
not as easy as that for unfractionated heparin). Most drug tory. Almost all of the many reports in the literature are
anecdotal, retrospective, small-to-modest in numbers,information sheets mention renal disease as a contra-
indication for the use of fractionated heparin. We advo- single-center, and rarely examine more than one inter-
vention treatment modality. Moreover, crucial details ofcate either unfractionated heparin, or prolonged use of
fractionated heparin only with simultaneous monitoring inclusion criteria, especially LV performance at the time
of intervention, are not always available, and the decisionof activated factor Xa levels.
(c) With the recent marked increase in the use of algorithms determining percutaneous transluminal coro-
nary angioplasty (PTCA) versus CABG are not alwayscoronary artery stenting (acutely and electively) there
has been intense interest in novel antiplatelet therapy, ideally clear, substantially reducing the validity of at-
tempted meta-analysis. Finally, one must always remem-for example, with agents that block platelet aggregation
(glycoprotein IIb/IIIa inhibitor abciximab, and ticlopi- ber the much shorter expected lifespan of renal patients
compared to non-uremic subjects in deciding how anddine/clopidrogel) [121, 122]. A recent study in 9 hemodi-
alysis patients found that clopidrogel had a significant when to intervene for CAD.
A number of clinical trials have taken place in theantiplatelet effect and was well tolerated, at conventional
doses [123]. Large-scale intervention trials have not in- general population, and a consensus about which pa-
tients should be offered revascularization has emerged.cluded uremic patients.
Revascularization is appropriate for improved survival
Stable and chronic CAD in “high-risk” patients, which include: those with left
main CAD; three vessel disease, moderate symptoms andTo achieve stable symptomatic coronary artery dis-
ease, our first maneuver is to optimize the hematocrit reduced LV function; and two-vessel disease with involve-
ment of the proximal LAD. In these high-risk patients(using blood, iron or erythropoietin). Correction by
erythropoietin of hematocrit from 25 to 35% increased CABG reduces the risk of subsequent myocardial in-
farction and improves survival [124]. Low risk patientsthe exercise duration from 361 95 to 488 117 seconds
(P 0.01), with ST-segment depression at indexed exercise include those with single vessel disease and good LV func-
tion; here, medical therapy and angioplasty or stentingfalling from 2.1  0.4 to 0.9  0.7 mm (P  0.01) [58].
Over-correction of the hematocrit to near-normal or nor- are appropriate as first interventions. Failure to achieve
symptom control would be an indication for CABG.mal values in patients with CAD should be avoided [111].
Long-acting calcium channel blockers are useful, and In contrast to this consensus, for uremic subjects in
whom we try to achieve the goals of intervention in CAD,well tolerated. It should be borne in mind that verapamil
and diltiazem can alter whole blood cyclosporine levels namely, securing relief from symptoms, prevention of
acute coronary events, improving prognosis, and to per-in renal transplant patients; thus, careful monitoring of
these levels is mandatory each time a transplant patient mit safer renal transplantation, the advice given in re-
views of this field can vary between angioplasty andstarts therapy, alters the drug dosage, or finishes treat-
ment. Beta-blockers are also useful, in part because not CABG on the grounds of success of the former
contrasted with mortality from the latter [125], andmany renal patients have severe LVH and LVH-associ-
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Table 1. Summary of seven recent studies reporting on coronary angioplasty/stenting in renal patients
Patients
Primary
Reference Year TX D CRF Age Diabetic Angina success CABG Restenosis F-U Mortality
[126] 1999 83 RT 42%
[127] 1999 6887 D 5.4%
[128] 1999 92 D 2% 1%
[129] 2000 87 D 58 16/87 52% 85–96% 0% 35% 12M 13%
[130] 2000 63 D 92% 24M 15%
[131] 2000 34 D 65 19/34 91% 35% 9M 18%
[132] 2001 15 RT 49 D 13 CRF 89% 26/77 24M 26/77
Abbreviations are: TX, transportation; D, dialysis; CRF, chronic renal failure; RT, renal transplantation; CABG, coronary artery bypass grafting; F-U, follow-up
period (months).
CABG and not angioplasty on the grounds of success compared clinical outcomes following PTCA for 77
of the former [62], with little excess mortality compared chronic renal failure (CRF; dialysis and non-dialysis)
to non-renal failure patients, versus the high restenosis patients and a control group matched for history of myo-
rate of the latter intervention. Coronary artery stenting, cardial revascularization, specific revascularization pro-
laser atherectomy, and other interventional refinements cedure, gender, age, diabetes, number of native vessels
add further layers of complexity. diseased, number of vessels dilated, and the specific ves-
sel(s) dilated [132]. CRF patients had a higher incidence
Coronary angioplasty (PTCA) and coronary artery of peripheral vascular disease, hypertension, and more
stenting (CAS) complex PTCA target lesion types than controls (5 vs.
16% Type A, 12 vs. 28% Type B1, 44 vs. 41% Type B2,There have been over 20 reports detailing PTCA ver-
sus CAS procedures in patients with chronic renal fail- 39 vs. 15% Type C; P  0.001). The primary success
rate for PTCA in CRF patients and controls was 89 andure, on dialysis or after renal transplantation in the last
two decades. We will focus on the all-too-few reports 97% (P  0.05). Survival analysis 24 months following
PTCA showed a lower composite cardiac event-free sur-with substantial patient numbers [126–132]. These have
reported in the last five years, and since the recent major vival (angiographic restenosis, myocardial infarction,
coronary artery bypass surgery, and cardiac death) forreviews in this area [58, 133].
Table 1 lists comparative information that can be de- those with CRF than controls (54 vs. 69%; P  0.002).
Over the study period, 26 CRF patients died (11 fromrived from the largest of these studies. The immediate
success rate is high: approximately 90% of patients have cardiac causes) compared to only 3 control patients (one
from a cardiac cause; P  0.001 for all cause and P abolished or improved angina pectoris.
Coronary artery angioplasty. The main focus of atten- 0.003 for cardiac mortality). PTCA results were also com-
pared between two categories of CRF patients. The firsttion on PTCA in this clinical context has been not the
immediate success rate, but the very high rate of subse- consisted of 49 ESRD patients on dialysis and the second
included 28 patients not on dialysis (13 with creatininequent restenosis (quoted values of 41 to 80%) [125],
compared to roughly 33% in non-diabetic non-uremic 190 mol/L and 15 with ESRD post-renal transplant).
Both subgroups had similar coronary anatomy, includingsubjects [134]. The reasons for this high restenosis rate
are not understood, but several factors must be consid- PTCA, target lesion type, and acute and long-term out-
comes. The observed primary success and complicationered: (1) the high proportion of uremic patients with
diabetes and CAD, and increased restenosis rates in rates for PTCA in CRF patients compared with controls
matched for comorbid features were deemed acceptablediabetics are well-described [135–137]; (2) hyperfibrino-
genemia in those patients showing angiographic evidence despite more complex target lesion morphology. Poorer
long-term outcomes, however, were apparent for thoseof restenosis, and/or raised fibrinogen levels compared
to non-uremic patients not showing restenosis [138]; (3) with CRF regardless of dialysis dependence and likely
relate to more extensive atherosclerosis and complexsmaller luminal diameter of affected vessels [85, 138],
most likely due to greater hyperplasia of vessel media target coronary lesions at index PTCA as well as other
features related to CRF.and intima [22]; and (4) a less satisfactory post-angio-
plasty result because of extensive coronary artery calci- We recommend that patients undergo re-angiography,
or the previously positive screening test, no later than 6fication [139].
There continues to be significant developments of, and to 12 months post-PTCA to try to detect these early
recurrences or poor interventional outcomes, especiallyimprovements in, interventional cardiological techniques.
Thus, the most recent report of PTCA in uremic patients if the patients are wait-listed for renal transplantation.
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Coronary artery stenting. Coronary artery stenting has vs. 2%, P  0.01). Thus, despite similar angiographic
results, patients with ESRD are at higher risk for targetshown greater long-term patency and promise. Le Feu-
vre reported a primary success rate of 96% in dialysis lesion revascularization after coronary stenting than con-
trols. Nonetheless, most patients with ESRD did notpatients [stenting for all lesions unless located after ex-
tensive tortuosity, in small vessels (2.5 mm diameter), develop restenosis after stent placement, suggesting an
important role for stenting in the management of thisor after an excellent anatomical angioplasty result (negli-
gible residual stenosis)]. The rate of repeat vasculariza- challenging population
In cardiology the Holy Grail to prevent restenosis aftertion for restenosis after primary stenting was similar in
21 dialysis and 187 non-dialysis patients (30 vs. 25%). At coronary interventions has been sought for two decades.
Two very promising new approaches may be of special usetwo years, the rate of repeat vascularization for disease
progression was the same in both groups, though the in uremic subjects: local brachytherapy (beta- or gamma-
radiation) [140] and, more remarkably, the use of coro-rate of cardiac death was much higher in the dialysis
cohort (15 vs. 5%) [125, 129]. These clinicians concluded nary stents impregnated with the immunomodulatory
drug rapamycin (sirolomus). The latter seems to possessthat the “accelerated restenosis” problem was more
likely to be the result of inadequate primary angioplasty, novel and extraordinary antiproliferative and anti-ath-
erogenic properties; it prevented atherosclerosis of theand argued that an angioplasty giving “stent-like results”
was an effective intervention. aorta in apolipoprotein-E knockout mice fed a high
cholesterol diet, and abrogated all myointimal prolifer-These assertions are borne out by two recent studies.
The first compared 63 coronary patients on hemodialysis ation following angioplasty in human coronary arteries
(RAVEL Study).with a reference group of 63 patients paired with respect
to gender, age, and the necessity or not of stent implanta- There are no reports of substance detailing the effect
of the newest invasive cardiological tools to deal withtion. There was a higher frequency of hypertension (79
vs. 39%) and of hypertriglyceridema (22 vs. 8%) in the complex CAD, which include cutting balloon, directional
or extraction atherectomy and laser angioplasty.hemodialysis group than in the controls. However, there
was no significant difference with respect to primary Also, there are no randomized studies comparing an-
gioplasty/stenting to medical management of uremic sub-success rate of angioplasty (92 and 89%, respectively),
nor to the development of early cardiovascular complica- jects with CAD. If such a study were to be undertaken,
the proportion of diabetic subjects, and symptomatictions (4 and 1.9%, respectively). After a two-year follow-
up, there was no significant difference in the restenosis versus asymptomatic subjects would need careful bal-
ancing.rate in the hemodialysis patients (33%) compared with
the controls (25%). Nevertheless, the mortality rate at
Open heart and bypass CABG and valve2 years was higher in the dialysis group (15%) compared
surgery in uremiawith the reference group (3.5%, P  0.03) [130].
The second study gathered data from a four-year pe- Dialysis and cardiothoracic surgery have evolved to-
gether. This fact added to the high prevalence of cardio-riod during which CAS was performed on 40 lesions in
34 patients with ESRD. These lesions were compared vascular problems in dialysis patients meant that very
soon after dialysis was established as a treatment mod-with 80 lesions from patients without renal disease who
underwent coronary stenting in the STARS and WINS ality, the two interventions coincided. The first reports
of cardiac surgery in patients with renal failure wereclinical trials, matched for treatment site, diabetes, lesion
length, and reference vessel diameter. Quantitative coro- simply to indicate the fact that it was possible successfully
to operate on dialysis patients [141, 142]. Also, earlynary angiography was performed on all lesions and clini-
cal outcomes were assessed at the nine-month follow- open-heart surgery produced a significant amount of
acute renal failure, and spurred on the provision of dial-up. Clinical and angiographic characteristics were well
matched between the two groups and acute clinical suc- ysis facilities. Much valuable information from these
early reports is summarized in three reviews [143–145].cess rates were similar. Despite comparable initial angio-
graphic results over the nine-month follow-up period, More detailed information is given in another publica-
tion [146].repeat target lesion revascularization was twice as fre-
quent in the ESRD group compared with the control Altogether there are nearly 100 accounts in about 1500
patients that report outcome data for cardiac surgerygroup (35 vs. 16%, P  0.05). After adjusting for differ-
ences in the post-procedural minimum lumen diameter (mainly CABG, but also valve surgery, aneurysm resec-
tion, and pericardiectomy) in patients with chronic renaland other angiographic and clinical characteristics, ESRD
remained the most important predictor of late target failure, on dialysis, and after renal transplantation.
One recent paper reported on 25 years of myocardiallesion revascularization (relative risk  2.3, P  0.04).
In addition, the overall nine-month mortality was higher revascularization (both PTCA and CABG) in 83 renal
transplantation patients from one institution. Thirty-for ESRD patients than for the control population (18
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eight patients were revascularized and then went on to vessel walls [153] that resemble those seen in uremia.
receive renal transplants, and 45 were revascularized Novel interventions may be necessary to ameliorate
after renal transplantation. Diabetes mellitus was the these problems [154, 155].
cause of renal failure in 42% of these patients. Standard Technical challenges. Some of the main technical sur-
coronary angiography, CABG, and PTCA techniques gical challenges to overcome include the increased diffi-
were used without periprocedural renal allograft loss. culty of anastomosing vessels onto calcified native vessels
Actuarial patient survival was 89%, 77%, and 65% at (for example, the ascending aorta or coronary arteries),
one, three, and five years after the last procedure (trans- and the avoidance of excessive handling of the aorta
plantation or revascularization), respectively. Cardiac lest calcific emboli produce ischemic sequela. There is
disease was the most common cause of death. Early- compelling evidence that the use of arterial grafts carries
phase risk factors for death by multivariate analysis in- the potential for a significantly longer graft patency pe-
cluded hypertension and revascularization before 1989. riod in non-uremic patients, but whether this is also the
Late-phase risk factors for death included diabetes melli- case for patients with renal disease has not been estab-
tus, higher number of pre-CABG myocardial infarctions, lished, and whether the use of internal mammary artery
renal transplantation before 1984, older age, and unsta- (IMA) will compromise sternal blood supply, or increase
ble angina before CABG. Myocardial revascularization
the risk of mediastinitis, in renal patients is not clear,
could be performed with acceptable short- and long-
though there was no evidence of these complications interm results in patients with renal disease who had renal
a recent study [156].transplantation either before or after the revasculariza-
Mortality. The overall peri-operative mortality in thistion procedure. Diabetes mellitus was a highly prevalent
diverse group of patients is several-fold that of non-condition among these patients, and cardiac disease was
uremic patients, and becomes a very significant factortheir most common mode of death. PTCA and CABG
where a heart valve and CABG are planned simultane-posed little risk for renal allograft loss [126]. The safety
ously. This increased mortality risk seems lowest forof renal allografts in patients undergoing coronary revas-
renal transplantation patients. LV performance at sur-cularization was also a feature of another recent report
gery is an important predictor of outcome in uremicfrom Hannover [147], where 42% of patients had NYHA
subjects, as it is in non-uremic subjects [95]. It also shouldIII symptoms, and 16% had NYHA IV symptoms, but
be remembered that a higher proportion of the subjectsthere were no perioperative deaths, no allografts lost to
in the uremic patients’ series were undergoing emer-acute perioperative or early post-operative organ rejec-
tion, and 88% one-year and 85% five-year cumulative gency surgery. Few series report more than one-year
patient survival rates. survival rates post-CABG, but at five years survival has
Complications. Ischemic complications post-bypass are been reported to be 48% [157], 40% [158], and 83%
more common in hemodialysis patients, and shunting [159]. These survivals are comparable with non-CABG
through an arteriovenous fistula has been mooted as one uremic subjects, and because of the much greater overall
possible reason for this problem; however, in a study of as well as cardiovascular mortality rates uremic patients
the oxygen consumption patterns during bypass it was suffer, these survival rates are inferior to those in non-
shown that that hemodialysis patients with a functional fis- uremic subjects (85% at 5 years [160]). There are no
tula had similar oxygen utilization to patients with chronic prospective randomized trials to use as a guide to com-
renal failure or normal renal function [148]. Other impor- pare medical therapy versus CABG (alone) in symptom-
tant post-operative complications that are affected by the atic uremic subjects with CAD.
presence of renal failure include sternal wound infections There are no studies in uremic subjects of two other
[149], and also post-bypass stroke (the risk increasing with
advances. The first of these is minimally-invasive bypass
age, aortic calcification, and renal dysfunction) [150].
surgery (with or without the use of cardiopulmonaryLittle worthwhile information exists about modulating
artery bypass which might improve the morbidity/infec-risk factors for saphenous vein bypass re-occlusion in
tion rates for uremic subjects (but is mostly confined torenal failure patients. Whereas in non-renal patients it is
left internal mammary artery to left anterior descendingclear that benefits continue to accrue from aggressive
artery [LIMA-LAD] revascularization, and requires acholesterol reduction (to at least 2.5 mmol/L LDL-cho-
longer anesthetic). The second technique is transmyocar-lesterol [151]), there have been no good accounts of the
dial laser revascularization (surgical or percutaneous),correlates of early restenosis in uremic patients, let alone
which has found favor in some specialized centers asany intervention trials. One report details the histological
a means of reducing coronary pain in the context offindings in bypass veins in a uremic patient dying some
“untreatable” coronary lesions. Given the severely re-years after CABG where intense intimal proliferation
duced frequency of symptomatic CAD in uremia, it iswas seen [152]. The bypass procedure itself excites in-
flammatory and thrombotic changes in the blood and not likely that this approach will be useful.
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Medical therapy versus coronary intervention this analysis, especially concerning the selection bias.
There are fewer reported data for renal transplantationin uremic CAD
patients, and fewer still for pre-dialysis patients, comparedThere has only been one randomized trial of revascu-
to dialysis patients. Even here, only one study examinedlarization versus medical therapy, and it is a study with
more than 100 patients, and very few studies includedan impact and influence that belie the tiny number of
or reported intra-institutional control data for primarysubjects involved. The 1992 Manske and colleagues’ in-
PTCA success and restenosis rates for non-uremic pa-vestigation was predicated on the fact that insulin-depen-
tients. In those studies that purport to “compare” PTCAdent diabetic patients found to have substantial coronary
with CABG, this has not been in the context of a random-artery disease at the time of assessment for renal trans-
ized trial, but after retrospective analysis and with insuf-plantation had a two-year survival of less than 50% [161].
ficient information as to why certain patients had PTCABecause most of these patients have no angina symptoms
as opposed to CABG, and vice versa.their management is controversial. The investigators
The findings of the BARI study may have a messageasked whether coronary artery revascularization in such
for uremic subjects, as it is the largest randomized trialpatients might decrease the combined incidence of unsta-
of CABG versus angioplasty to date: 1829 patients wereble angina, myocardial infarction, and cardiac death. A
randomized and followed for over five years [163]. How-total of 151 consecutive insulin-dependent diabetic can-
ever, in the subgroup with diabetes the five-year mortalitydidates for renal transplantation underwent coronary an-
for CABG was 19% and for PTCA was 35% (P 0.003).giography; 31 had stenoses greater than 75% in one or
Of the retrospective series (where confounding vari-more coronary arteries, atypical chest pain or no chest
ables of prognostic importance could not be matched,pain, and a left ventricular ejection fraction greater than
for example, diabetes, degree of CAD), two fairly recent0.35. Of these, 26 agreed to be randomly assigned medi-
studies are consistent. The first study included 84 chroniccal treatment (a calcium-channel-blocking drug plus as-
dialysis patients with symptomatic coronary artery dis-pirin) or revascularization (angioplasty or coronary by-
ease without prior revascularization. Twenty-four pa-pass surgery). Ten of 13 medically managed and 2 of 13
tients underwent PTCA of one or more vessels, and 60
revascularized patients had a cardiovascular endpoint
patients underwent CABG. Recurrence of angina, MI,
within a median of 8.4 months of coronary angiography cardiac death, and all-cause death following revasculari-
(P  0.01), while four medically managed patients died zation, as well as the number of inpatient days’ pre-
of myocardial infarction during follow-up. Thus, revascu- procedure and post-procedure events were recorded.
larization decreased the frequency of cardiac events in The two patient groups were comparable in terms of
insulin-dependent diabetic patients with chronic renal age, sex, history of MI, LV mass and function, and angina
failure and symptomless coronary artery stenoses. These severity. Diabetes mellitus was more prevalent in the
findings suggest that diabetic renal transplant candidates PTCA group, while the CABG group had more severe
should be screened for silent coronary artery disease, coronary artery disease. The two-year survival rate of
because revascularization may decrease cardiac morbid- the CABG patients (66%; 95% confidence interval 53
ity and mortality in this population. This remains the to 79) did not differ from that of the PTCA patients
sole attempt to answer this point, and sadly now is flawed (51%; 95% confidence interval 27 to 65). Thirteen PTCA
by the fact that medical intervention in 2001 is likely to patients were restudied 106  108 days after recurrence
be more complex and aggressive than was the case a of angina, and nine (69%) of these patients were found
decade ago. Particularly in diabetic patients with CAD, to have angiographic restenosis. The post-procedure risk
the use of a beta-blockade [162] and intensive lipid- of angina and the combined endpoints of angina, MI, and
lowering therapy now need to be put up against direct cardiovascular death were significantly greater following
intracoronary interventions. PTCA than CABG. Percutaneous transluminal coronary
angioplasty was the only consistent predictor of outcomes;
PTCA versus CABG in uremic CAD the adjusted relative risks (compared with CABG) of
There are no prospective randomized trials comparing post-procedure angina and combined endpoints were
PTCA and CABG in uremic subjects. 16.4 and 10.2, respectively, and were several-fold higher
Herzog, Ma and Collins’ analysis of the data from the than the unadjusted risks [158].
USRDS (1978 to 1995), with 7419 dialysis patients under- The second retrospective study comprised 23 CABG
going CABG, and 6887 patients having PTCA, showed a patients and 20 coronary angioplasty patients undergoing
higher in-hospital mortality with surgery (12.5% vs. 5.4%), chronic renal dialysis [159]. Among the CABG patients,
but the two-year cardiac event-free (cardiac death and there were no hospital deaths. The graft patency rate was
MI) survival rates were better for CABG than PTCA 100% for arterial grafts. There were four late deaths and
(62% vs. 71.3%, P 0.02) [127]. Impressive though these four cardiac events. In the coronary angioplasty patients,
the lesion success rate was 76%. There were no hospitalnumbers of subjects may be, there are many caveats to
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deaths and three major complications. The restenosis tients (and there is no good evidence that this is the case),
and (3) If it could not be expected that patients wouldrate was 70%. There were two late deaths and 14 cardiac
events. The five-year cardiac event-free rate was 70% in live long enough for “protection” to take effect. It is cer-
tainly true that the mortality of patients on dialysis isthe CABG patients, significantly better than the 18%
rate in coronary angioplasty patients (P  0.001). very great, but especially for younger patients and trans-
planted patients there is still the likely prospect of ex-The ideal trial would randomize balanced numbers of
diabetic and non-diabetic uremic patients into medical tended survival, and it is precisely in these groups where
interventional effort needs to be most concentrated.therapy versus immediate stenting or CABG (with iden-
tical medical therapy comprising best practice including All the available evidence suggests that CAD in ure-
mia, and indeed cardiovascular disease in its broadestanti-platelet agents, beta-blockers, aggressive lipid-low-
ering therapy, BP control and reduction in homocys- sense, tends to resemble that seen in old age and diabe-
tes. Common features include dysautonomia, vessel wallteine). Where possible it should carefully stratify the
groups into symptomatic versus non-symptomatic dis- intimal proliferation, and medial arterial calcification.
There is no convincing case that the types of interven-ease, LV function, and for entry CAD characteristics
such as number of vessels involved, degree of stenoses, tions proposed are unsafe in these populations when
carefully targeted and responsibly used. Based on theand calcifications. We feel that only a large multicenter
trial could aspire to such rigorous requirements, and note current overall survival data, patients should expect to
survive long enough on dialysis or after renal trans-the virtual absence of such trials in many therapeutic
areas of relevance to uremic patients. plantation to see a benefit from these interventions. We
feel that for maximal CVD protection in uremic subjects,
several risk factors will need to be tackled at once. As
CONCLUSIONS
yet the relative importance of the risk factors is not clear,
Coronary artery disease is clinically significant (if not and indeed is likely to be different for a patient with
always clinically evident) in a large proportion of patients mild renal insufficiency compared to patients on dialysis
with renal disease. This is true at whatever stage of renal or after renal transplantation.
disease the patient presents or is investigated. Most often Despite the lack of formal intervention evidence, we
the discovery of CAD is in the context of renal trans- recommend targeting all dialysis patients with overt car-
plantation work-up, or after symptoms or coronary events diovascular disease and attempting to reduce total cho-
when on dialysis. However, it is likely that the process lesterol below 5 mmol/L with statins (not a diet, as most
has begun at an earlier stage, and attention to earlier risk dialysis patients are calorifically challenged) and BP to
factor management seems sensible advice. In particular 140/90 mm Hg [164]. A large multicenter study of the
long-term control of BP, cholesterol and calcium-phos- use of atorvastatin in dialysis patients (CHORUS) will
phate balance may help prevent the formation of diffuse give a clear lead on this issue shortly. We try to reduce
calcified coronary (and other arterial) lesions. the BP to below 130/80 mm Hg in our renal transplant
While we know much more at the start of the 21st patients, which often requires three or more antihyper-
century about some aspects of the natural history of tensive drugs. The fundamental BP therapy (that is, the
CAD in these cohorts, we are hampered by a virtual first line of treatment) we believe should be an ACE-
absence of any specific intervention trial data. In the inhibitor (or angiotensin-antagonist) in view of its anti-
absence of clear guidance therapeutic nihilism has flour- atherosclerotic or pro-endothelial action and its ability
ished. However, as the evidential trickle has become a to improve arterial rigidity (the abnormality of which,
torrent in non-renal clinical areas, it is progressively with anemia, underpins the great excess of LVH seen in
more difficult to sustain this approach. There are only uremic subjects).
three possible justifications for avoiding cardiovascular- Our guide in post-transplantation lipid-lowering inter-
protective interventions in renal patients: (1) If CAD ventions is the Framingham cardiovascular risk calcula-
were a completely different entity in patients with uremia tion [165], despite its origins from a very different popu-
compared to those with normal renal function, with dif- lation. Then lipid-lowering treatment is given to all
ferent promoters and a different natural history. While patients with overt cardiovascular disease, to all diabet-
the degree of calcification is certainly greater than com- ics, and to all those with a ten-year absolute total cardio-
monly seen in non-uremic subjects, the CAD pattern in vascular risk exceeding 15%. On this basis one in three of
uremia in fact resembles that seen in old age and diabe- our renal transplant patients currently receives a statin.
tes. We feel that the calcification in the lesions may in Given the wide choice of effective immunosuppressive
fact reduce the chance of acute rupture, but the price agents at our disposal, many of which adversely affect
paid is their resistance to conventional non-surgical car- cardiovascular risk factors such as blood pressure [166],
diological intervention. (2) If the interventions proposed lipids [167] and blood glucose [168], it is now possible
to select an immunosuppressive regime tailored to the CVwere known to be unacceptably hazardous in renal pa-
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